Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains
Open accessPublished version of a preprint
Abstract
Background: The degree of heterotypic immunity induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains is a major determinant of the spread of emerging variants and the success of vaccination campaigns, but remains incompletely understood. Methods: We examined the immunogenicity of SARS-CoV-2 variant B.1.1.7 (Alpha) that arose in the United Kingdom and spread globally. We determined titres of spike glycoprotein-binding antibodies and authentic virus neutralising antibodies induced by B.1.1.7 infection to infer homotypic and heterotypic immunity. Results: Antibodies elicited by B.1.1.7 infection exhibited significantly reduced recognition and neutralisation of parental strains or of the South Africa variant B.1.351 (Beta) than of the infecting variant. The drop in cross-reactivity was significantly more pronounced following B.1.1.7 than parental strain infection. Conclusions: The results indicate that heterotypic immunity induced by SARS-CoV-2 variants is asymmetric. Funding: This work was supported by the Francis Crick Institute and the Max Planck Institute for Dynamics of Complex Technical Systems, Magdeburg.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Of 34 convalescent plasma samples from persons infected with the Alpha variant, 59% had 3-fold to 10-fold reduced neutralizing activity and 18% had >10-fold reduced neutralizing activity to the Beta variant.
“Of 34 convalescent plasma samples from persons infected with the Alpha variant, 59% had 3-fold to 10-fold reduced neutralizing activity and 18% had >10-fold reduced neutralizing activity to the Beta variant 99,104,221 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209 · see citing works
IQ-TREE: A Fast and Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies
Nguyen, L.-T., Schmidt, H. A., von Haeseler, A., & Minh, B. Q. (2015) · Molecular Biology and Evolution · doi:10.1093/molbev/msu300 · Cited by 26,046 · see citing works
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876 · see citing works
Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · doi:10.1101/2021.01.25.428137 · Cited by 2,328
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312 · see citing works
Data, disease and diplomacy: GISAID's innovative contribution to global health
Elbe, S., & Buckland‐Merrett, G. (2017) · Global Challenges · doi:10.1002/gch2.1018 · Cited by 1,928 · see citing works
Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860 · see citing works
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674 · see citing works
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01285-x · Cited by 1,147 · see citing works
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.037 · Cited by 992 · see citing works
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans
Ng, K. W., Faulkner, N., Cornish, G. H., Rosa, A., Harvey, R., Hussain, S., Ulferts, R., Earl, C., Wrobel, A. G., Benton, D. J., et al. (2020) · Science · doi:10.1126/science.abe1107 · Cited by 886 · see citing works
Self-citationChen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881 · see citing works
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697 · see citing works
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669 · see citing works
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Network for Genomic Surveillance in South Africa, Cele, S., COMMIT-KZN Team, Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03471-w · Cited by 651 · see citing works
Self-citationEscape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
Cele, S., Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., et al. (2021) · doi:10.1101/2021.01.26.21250224 · Cited by 651 · see citing works
Self-citationEmary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00628-0 · Cited by 603 · see citing works
Neutralizing Activity of BNT162b2-Elicited Serum
Liu, Y., Liu, J., Xia, H., Zhang, X., Fontes-Garfias, C. R., Swanson, K. A., Cai, H., Sarkar, R., Chen, W., Cutler, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102017 · Cited by 537 · see citing works
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
Wall, E. C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P., Hatipoglu, E., Ngai, Y., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01290-3 · Cited by 491 · see citing works
Self-citationFrampton, D., Rampling, T., Cross, A., Bailey, H., Heaney, J., Byott, M., Scott, R., Sconza, R., Price, J., Margaritis, M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00170-5 · Cited by 387 · see citing works
Self-citationNew variant of SARS-CoV-2 in UK causes surge of COVID-19
Kirby, T. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00005-9 · Cited by 319 · see citing works
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
Edara, V. V., Norwood, C., Floyd, K., Lai, L., Davis-Gardner, M. E., Hudson, W. H., Mantus, G., Nyhoff, L. E., Adelman, M. W., Fineman, R., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.009 · Cited by 224 · see citing works
Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers
Houlihan, C. F., Vora, N., Byrne, T., Lewer, D., Kelly, G., Heaney, J., Gandhi, S., Spyer, M. J., Beale, R., Cherepanov, P., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31484-7 · Cited by 219 · see citing works
Self-citationSkelly, D. T., Harding, A. C., Gilbert-Jaramillo, J., Knight, M. L., Longet, S., Brown, A., Adele, S., Adland, E., Brown, H., Team, M. L., et al. (2021) · doi:10.21203/rs.3.rs-226857/v1 · Cited by 216 · see citing works
(2021) · doi:10.1038/s41467-021-25167-5 · Cited by 216 · see citing works
Self-citationSkelly, D. T., Harding, A. C., Gilbert-Jaramillo, J., Knight, M. L., Longet, S., Brown, A., Adele, S., Adland, E., Brown, H., Team, M. L., et al. (2021) · doi:10.21203/rs.3.rs-226857/v2 · Cited by 216 · see citing works
Self-citationSARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodiesPreprint
Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B., Kgagudi, P., Tegally, H., Iranzadeh, A., et al. (2021) · bioRxiv · doi:10.1101/2021.03.06.434193 · Cited by 134 · see citing works
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B. E., Kgagudi, P., Tegally, H., Iranzadeh, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104192 · Cited by 128 · see citing works
AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC
Wall, E. C., Wu, M., Harvey, R., Kelly, G. P., Warchal, S., Sawyer, C., Daniels, R. S., Adams, L., Hobson, P. S., Hatipoglu, E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01462-8 · Cited by 116 · see citing works
Self-citationBrown, J. C., Goldhill, D. H., Zhou, J., Peacock, T. P., Frise, R., Goonawardane, N., Baillon, L., Kugathasan, R., Pinto, A., McKay, P. F., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.24.432576 · Cited by 68 · see citing works
Grant, P. R., Turner, M., Shin, G. Y., Nastouli, E., & Levett, L. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.06.028316 · Cited by 66 · see citing works
Self-citationEdara, V. V., Norwood, C., Floyd, K. A., Lai, L., Davis-Gardner, M. E., Hudson, W. H., Mantus, G. E., Nyhoff, L. E., Adelman, M. W., Fineman, R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.20.432046 · Cited by 37 · see citing works
Emergence of a novel subclade of influenza A(H3N2) virus in London, December 2016 to January 2017
Harvala, H., Frampton, D., Grant, P. R., Raffle, J., Ferns, R. B., Kozlakidis, Z., Kellam, P., Pillay, D., Hayward, A. C., & Nastouli, E. (2017) · Eurosurveillance · doi:10.2807/1560-7917.es.2017.22.8.30466 · Cited by 36 · see citing works
Self-citationScalable and robust SARS-CoV-2 testing in an academic center
Aitken, J., Ambrose, K., Barrell, S., Beale, R. C. L., Bineva‐Todd, G., Biswas, D., Byrne, R. D., Caidan, S., Cherepanov, P., Churchward, L., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0588-y · Cited by 32 · see citing works
Self-citationSARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · doi:10.1101/2021.01.18.427166
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528 · see citing works
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009 · see citing works
Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J., Triccas, J. A., Khoury, D. S., & Davenport, M. P. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00267-6 · Cited by 590 · see citing works
Novel SARS-CoV-2 variants: the pandemics within the pandemic
Boehm, E., Kronig, I., Neher, R. A., Eckerle, I., Vetter, P., & Kaiser, L. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.022 · Cited by 341 · see citing works
Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection
Israel, A., Shenhar, Y., Green, I., Merzon, E., Golan‐Cohen, A., Schäffer, A. A., Ruppin, E., Vinker, S., & Magen, E. (2021) · Vaccines · doi:10.3390/vaccines10010064 · Cited by 218 · see citing works
COVID-19 vaccination: The road ahead
Altmann, D. M., & Boyton, R. J. (2022) · Science · doi:10.1126/science.abn1755 · Cited by 195 · see citing works
Fendler, A., Shepherd, S. T. C., Au, L., Wilkinson, K. A., Wu, M., Byrne, F., Cerrone, M., Schmitt, A. M., Joharatnam‐Hogan, N., Shum, B., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00274-w · Cited by 170 · see citing works
Self-citationEmerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy
Ramesh, S., Govindarajulu, M., Parise, R. S., Neel, L. T., Shankar, T., Patel, S., Lowery, P., Smith, F., Dhanasekaran, M., & Moore, T. (2021) · Vaccines · doi:10.3390/vaccines9101195 · Cited by 152 · see citing works
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants
Reynolds, C. J., Gibbons, J. M., Pade, C., Lin, K., Sandoval, D. M., Pieper, F. P., Butler, D. K., Liu, S., Otter, A. D., Joy, G., et al. (2022) · Science · doi:10.1126/science.abm0811 · Cited by 126 · see citing works
Dupont, L., Snell, L., Graham, C., Seow, J., Merrick, B., Lechmere, T., Maguire, T., Hallett, S. R., Pickering, S., Charalampous, T., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00974-0 · Cited by 98 · see citing works
RETRACTED: SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies
Ng, K. W., Faulkner, N., Finsterbusch, K., Wu, M., Harvey, R., Hussain, S., Greco, M., Liu, Y., Kjær, S., Swanton, C., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn3715 · Cited by 95 · see citing works
Self-citationRetractedThree-dose vaccination elicits neutralising antibodies against omicron
Wu, M., Wall, E. C., Carr, E. J., Harvey, R., Townsley, H., Mears, H. V., Adams, L., Kjær, S., Kelly, G. P., Warchal, S., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00092-7 · Cited by 91 · see citing works
Self-citationBekliz, M., Adea, K., Vetter, P., Eberhardt, C. S., Hosszu-Fellous, K., Vu, D., Puhach, O., Essaidi-Laziosi, M., Waldvogel‐Abramowski, S., Stephan, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31556-1 · Cited by 91 · see citing works
Fendler, A., Au, L., Shepherd, S. T. C., Byrne, F., Cerrone, M., Boos, L. A., Rzeniewicz, K., Gordon, W., Shum, B., Gerard, C. L., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00275-9 · Cited by 87 · see citing works
Self-citationOne year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages
Gónzález‐Candelas, F., Shaw, M., Phan, T. G., Kulkarni‐Kale, U., Paraskevis, D. N., Luciani, F., Kimura, H., & Sironi, M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104869 · Cited by 65 · see citing works
A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy
Greaney, A. J., Starr, T. N., Eguia, R. T., Loes, A. N., Khan, K., Karim, F., Cele, S., Bowen, J., Logue, J. K., Corti, D., et al. (2021) · bioRxiv · doi:10.1371/journal.ppat.1010248 · Cited by 71 · see citing works
Self-citationSouza, P. F. N., Mesquita, F. P., Amaral, J. L., Landim, P. G. C., Lima, K. R. P., Costa, M. B., Farias, I. R., Belém, M. O., Pinto, Y. O., Moreira, H. H. T., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.03.058 · Cited by 65 · see citing works
Proust, A. M., Queval, C. J., Harvey, R., Adams, L., Bennett, M., & Wilkinson, R. J. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02861-3 · Cited by 57 · see citing works
Self-citationDifferential Pathogenesis of SARS-CoV-2 Variants of Concern in Human ACE2-Expressing Mice
Natekar, J. P., Pathak, H., Stone, S., Kumari, P., Sharma, S., Auroni, T. T., Arora, K., Rothan, H. A., & Kumar, M. (2022) · Viruses · doi:10.3390/v14061139 · Cited by 52 · see citing works
Understanding the Molecular Biology of SARS-CoV-2 and the COVID-19 Pandemic: A Review
Alsobaie, S. F. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s306441 · Cited by 42 · see citing works
SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodiesPreprint
Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B., Kgagudi, P., Tegally, H., Iranzadeh, A., et al. (2021) · bioRxiv · doi:10.1101/2021.03.06.434193 · Cited by 134 · see citing works
da Silva, S. J. R., de Lima, S. C., da Silva, R. C., Kohl, A., & Pena, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.836826 · Cited by 36 · see citing works
Upasani, V., Townsend, K., Wu, M., Carr, E. J., Hobbs, A., Dowgier, G., Ragno, M., Herman, L. S., Sharma, S., Shah, D., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad368 · Cited by 34 · see citing works
Self-citationWinklmeier, S., Eisenhut, K., Taskin, D., Rübsamen, H., Gerhards, R., Schneider, C., Wratil, P. R., Stern, M., Eichhorn, P., Keppler, O. T., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103659 · Cited by 30 · see citing works
Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27 · see citing works
Tut, G., Lancaster, T., Krutikov, M., Sylla, P., Bone, D., Spalkova, E., Bentley, C., Amin, U., Jadir, A., Hulme, S., et al. (2023) · Nature Aging · doi:10.1038/s43587-022-00328-3 · Cited by 24 · see citing works
Self-citationFendler, A., Shepherd, S. T. C., Au, L., Wu, M., Harvey, R., Wilkinson, K. A., Schmitt, A. M., Tippu, Z., Shum, B., Farag, S., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100781 · Cited by 23 · see citing works
Self-citationPrevious SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals
Trinité, B., Pradenas, E., Marfil, S., Rovirosa, C., Urrea, V., Tarrés-Freixas, F., Ortiz, R., Rodon, J., Vergara‐Alert, J., Segalés, J., et al. (2021) · Viruses · doi:10.3390/v13061135 · Cited by 20 · see citing works
Furukawa, K., Tjan, L. H., Sutandhio, S., Kurahashi, Y., Iwata, S., Tohma, Y., Sano, S., Nakamura, S., Nishimura, M., Arii, J., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab430 · Cited by 22 · see citing works
Heterologous humoral immunity to human and zoonotic coronaviruses: Aiming for the achilles heel
Ng, K. W., Faulkner, N., Wrobel, A. G., Gamblin, S. J., & Kassiotis, G. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101507 · Cited by 19 · see citing works
Self-citationElliott, T., Cheeseman, H. M., Evans, A. B., Day, S., McFarlane, L. R., O’Hara, J., Kalyan, M., Amini, F., Cole, T., Winston, A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010885 · Cited by 21 · see citing works
Zhang, S., Ma, P., Orzechowski, M., Lemmer, A., Rzasa, K. M., Bagnall, J., Barkho, S., Chen, M., He, L. L., Neitupski, R., et al. (2023) · mBio · doi:10.1128/mbio.03523-22 · Cited by 16 · see citing works
Lyski, Z. L., Brunton, A. E., Strnad, M., Sullivan, P. E., Siegel, S. A. R., Tafesse, F., Slifka, M. K., & Messer, W. B. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab585 · Cited by 15 · see citing works
The health of influenza surveillance and pandemic preparedness in the wake of the COVID-19 pandemic
Daniels, R. S., & McCauley, J. W. (2023) · Journal of General Virology · doi:10.1099/jgv.0.001822 · Cited by 16 · see citing works
Self-citationElsharkawy, A., Jahantigh, H. R., Guglani, A., Stone, S., Arora, K., & Kumar, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1557535 · Cited by 11 · see citing works
Neale, I., Ali, M., Kronsteiner, B., Longet, S., Abraham, P., Deeks, A. S., Brown, A., Moore, S. C., Stafford, L., Dobson, S. L., et al. (2023) · mBio · doi:10.1128/mbio.01212-23 · Cited by 11 · see citing works
Self-citationVinzón, S. E., Lopez, M. V., Cafferata, E. G. A., Soto, A. S., Berguer, P. M., Vázquez, L., Nusblat, L., Pontoriero, A., Belotti, E. M., Salvetti, N. R., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00737-4 · Cited by 8 · see citing works
Rare COVID reactions might hold key to variant-proof vaccines
Callaway, E. (2021) · Nature · doi:10.1038/d41586-021-00722-8 · Cited by 7 · see citing works
Nguyen, D. V., Xiao, J. H., Peter Simmonds, K., Lamikanra, A., Odon, V., Ratcliff, J. D., Townsend, A., Roberts, D. J., & Harvala, H. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab563 · Cited by 6 · see citing works
Can proteomics-based approaches further help COVID-19 prevention and therapy?
Kumar, V. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1924684 · Cited by 6 · see citing works
Embong, A., Nguyen-Contant, P., Wang, J., Kanagaiah, P., Chaves, F., Fitzgerald, T., Zhou, Q., Kosoy, G., Branche, A., Miller, B. L., et al. (2022) · Pathogens · doi:10.3390/pathogens11020186 · Cited by 4 · see citing works
Third exposure to COVID-19 infection or vaccination differentially impacts T cell responses
Ahimbisibwe, G., Greenwood, D., Wilkinson, K. A., Gahir, J., Townsley, H., Miah, M., Bawumia, P., Chaloner, C., Levi, D., Hobson, P. S., et al. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106598 · Cited by 3 · see citing works
Self-citationNeale, I., Ali, M., Kronsteiner, B., Longet, S., Abraham, P., Deeks, A. S., Brown, A., Moore, S. C., Stafford, L., Dobson, S. L., et al. (2023) · medRxiv · doi:10.1101/2023.02.16.23285748 · Cited by 3 · see citing works
Self-citationNawaz, S., Janiad, S., Fatima, A., Saleem, M., Fatima, U., & Ali, A. (2024) · Infectious Disorders - Drug Targets · doi:10.2174/0118715265271109231129112515 · Cited by 2 · see citing works
The T cell receptor repertoire reflects the dynamics of the immune response to vaccinationPreprint
Mohammed, K., Meadows, A., Hekmaty, S., Hatem, S., Simon, V. R., Jayaprakash, A. D., & Sachidanandam, R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.09.471735 · Cited by 2 · see citing works
Dowgier, G., Hobbs, A., Greenwood, D., Shawe‐Taylor, M., Stevenson-Leggett, P., Bazire, J., Penn, R., Harvey, R., Libri, V., Kassiotis, G., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.126960 · Cited by 2 · see citing works
Self-citationBroad human and animal coronavirus neutralisation by SARS-CoV-2 S2-targeted vaccinationPreprint
Ng, K. W., Faulkner, N., Finsterbusch, K., Wu, M., Harvey, R., Hussain, S., Greco, M., Liu, Y., Kjær, S., Swanton, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.30.470568 · Cited by 1 · see citing works
Self-citationAccurate evaluation of live-virus microneutralization for SARS-CoV-2 variant JN.1Preprint
Dowgier, G., Hobbs, A., Greenwood, D., Shawe‐Taylor, M., Stevenson-Leggett, P., Bazire, J., Penn, R., Harvey, R., Crick COVID serology pipeline, L. I., Libri, V., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.17.589886
Self-citationGreenwood, D., Hague, O., Kwesi‐Maliepaard, E. M., Redman, S. A., the HERITAGE study team, Legacy Investigators, WINDFall Study Team, Scott, F., Anzinger, J. J., Awandare, G. A., et al. (2025) · medRxiv · doi:10.1101/2025.06.13.25329588
Self-citationCole, M. E., Jossi, S., Dillen, C., Fanaroff, R. E., Frieman, M. B., & Pleguezuelos, O. (2026) · Vaccines · doi:10.3390/vaccines14040288
Translating viral genetic data to PRRSV-2 cross-neutralization using machine learning
Pamornchainavakul, N., Huang, J., Paploski, I. A. D., Makau, D. N., Ferreira, C. P., Krishna, V. D., Schroeder, D. C., Cheeran, M. C. ‐., & VanderWaal, K. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1875393
Tut, G., Lancaster, T., Sylla, P., Bone, D., Bentley, C., Jadir, A., Bruton, R. K., Spencer, K., Mallick, S., Elzaidi, A., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0354079
Self-citation
- Authors
- Faulkner, N., Ng, K. W., Wu, M. Y., Harvey, R., Margaritis, M., Paraskevopoulou, S., Houlihan, C., Hussain, S., Greco, M., Bolland, W., Warchal, S., Heaney, J., Rickman, H., Spyer, M., Frampton, D., Byott, M., de Oliveira, T., Sigal, A., Kjaer, S., Swanton, C., Gandhi, S., Beale, R., Gamblin, S. J., McCauley, J. W., Daniels, R. S., Howell, M., Bauer, D., Nastouli, E., & Kassiotis, G.
- Affiliations
- The Francis Crick Institute (GB)
- University College London Hospitals NHS Foundation Trust (GB)
- Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom
- University College London (GB)
- School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
- Max Planck Institute for Infection Biology (DE)
- Structural Biology STP, London, United Kingdom
- Corresponding author
- Nastouli, Eleni
- Kassiotis, George
- ORCID
- Faulkner, Nikhil
- Ng, Kevin W
- Wu, Mary Y
- Harvey, Ruth
- Margaritis, Marios
- Houlihan, Catherine
- Hussain, Saira
- Greco, Maria
- Bolland, William
- Rickman, Hannah
- Byott, Matthew
- Sigal, Alex
- Kjaer, Svend
- Swanton, Charles
- Gandhi, Sonia
- Beale, Rupert
- McCauley, John W
- Daniels, Rodney Stuart
- Howell, Michael
- Bauer, David
- Nastouli, Eleni
- Kassiotis, George
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2021-07-29
- Volume
- 10
- ISSN
- 2050-084X (ISSN-L)
- PMC
- PMC8352583
- OpenAlex
- W3183485637
- Cited by
- 52
- References
- 31
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 2 · 2023: 8 · 2022: 12 · 2021: 23
- FWCI
- 3.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- eLife (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Francis Crick Institute
- Max Planck Institute for Dynamics of Complex Technical Systems Magdeburg
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- SARS-CoV-2, B.1.1.7 Alpha variant, antibody cross-reactivity, heterotypic immunity, virus neutralising antibodies, natural infection, emerging variants, COVID-19 pandemic
- MeSH terms
- COVID-19, SARS-CoV-2, Antibodies, Viral, Cross Reactions, United Kingdom, Humans, Parents, South Africa, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
